Prospective Cohort Study Evaluating Iron Supplementation in Patients With Altered Iron Status in the Context of Acute Inflammation (CARMI (CARence Martiale & Inflammation))
Launched by UNIVERSITY HOSPITAL, GRENOBLE · Jun 6, 2025
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called CARMI, is studying the effects of iron supplements on patients who have anemia (low blood count) and are experiencing inflammation (swelling or irritation in the body). Specifically, it focuses on patients whose iron levels are not normal, characterized by certain lab results. The goal is to see if taking iron supplements helps improve their hemoglobin levels, which is a key indicator of how well their blood can carry oxygen, three months after they leave the hospital.
To be eligible for the study, participants must be hospitalized with anemia and signs of inflammation within the first three days. They should also have specific iron level measurements that fall into a particular range. However, there are certain conditions that would exclude someone from participating, such as recent blood transfusions or ongoing treatments that could affect the study results. If you or a loved one meet the criteria, participating in this study could help us understand better ways to treat anemia in patients dealing with inflammation.
Gender
ALL
Eligibility criteria
- Inclusion Criteria :
- • Anemia (Hb \< 130 g/L in men and \< 120 g/L in women) within the first 3 days of hospitalization in the department
- • Biological signs of inflammation (CRP ≥ 30 mg/L) within the first 3 days of hospitalization in the department
- • Ferritin between 30 and 300 µg/L and a transferrin saturation coefficient (TSC) \< 20% within the first 3 days of hospitalization in the department
- Exclusion Criteria :
- • Patients who object to the use of their data for research purposes
- • Patients unable to provide informed consent to participate in the research
- • Patients who received a red blood cell transfusion during hospitalization or in the month prior
- • Patients receiving erythropoietin (EPO) treatment
- • Patients treated with iron supplementation within one month prior to hospitalization
- • Congenital hemoglobinopathy (e.g., thalassemia, sickle cell disease)
- • Chemotherapy within the past 3 months or planned chemotherapy within the next 3 month
About University Hospital, Grenoble
The University Hospital of Grenoble is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and comprehensive patient care. As a prominent sponsor of clinical trials, the hospital leverages its expertise in various medical disciplines to facilitate cutting-edge studies that aim to improve treatment outcomes and enhance patient safety. With a strong commitment to collaboration, the University Hospital of Grenoble engages in partnerships with academic institutions, industry leaders, and regulatory bodies to drive scientific discovery and translate research findings into clinical practice. Its state-of-the-art facilities and multidisciplinary teams ensure rigorous adherence to ethical standards and regulatory guidelines, fostering an environment where groundbreaking research can thrive.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
La Tronche, , France
Patients applied
Trial Officials
Alexis BOCQUET, Hospital Doctor
Principal Investigator
University Hospital, Grenoble Alpes
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported